BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 35489393)

  • 21. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
    Sutton MN; Gammon ST; Muzzioli R; Pisaneschi F; Radaram B; Yang P; Piwnica-Worms D
    Mol Imaging Biol; 2022 Jun; 24(3):498-509. PubMed ID: 34905147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
    Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
    Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ
    Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
    Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
    BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer.
    Wang YY; Li L; Liu XJ; Miao QF; Li Y; Zhang MR; Zhen YS
    J Pharm Anal; 2022 Apr; 12(2):232-242. PubMed ID: 35582405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
    Yip-Schneider MT; Nakshatri H; Sweeney CJ; Marshall MS; Wiebke EA; Schmidt CM
    Mol Cancer Ther; 2005 Apr; 4(4):587-94. PubMed ID: 15827332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
    Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
    J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.
    Liu XJ; Li L; Liu XJ; Li Y; Zhao CY; Wang RQ; Zhen YS
    Int J Nanomedicine; 2017; 12():5255-5269. PubMed ID: 28769562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eicosapentaenoic Acid Inhibits
    Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
    Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
    Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.
    Radhakrishnan P; Bryant VC; Blowers EC; Rajule RN; Gautam N; Anwar MM; Mohr AM; Grandgenett PM; Bunt SK; Arnst JL; Lele SM; Alnouti Y; Hollingsworth MA; Natarajan A
    Clin Cancer Res; 2013 Apr; 19(8):2025-35. PubMed ID: 23444213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.
    Elechalawar CK; Rao G; Gulla SK; Patel MM; Frickenstein A; Means N; Roy RV; Tsiokas L; Asfa S; Panja P; Rao C; Wilhelm S; Bhattacharya R; Mukherjee P
    ACS Nano; 2023 May; 17(10):9326-9337. PubMed ID: 37129853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
    Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
    Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells.
    Duan Y; Yin X; Lai X; Liu C; Nie W; Li D; Xie Z; Li Z; Meng F
    Technol Cancer Res Treat; 2020; 19():1533033819895494. PubMed ID: 32336215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
    Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
    Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
    Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
    Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-κB activation.
    Li K; Zhou Y; Chen Y; Zhou L; Liang J
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):699-709. PubMed ID: 32185482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
    Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
    Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.